Concurrent with the clinical development of CA4P (combretastatin A4-phosphate or fosbretabulin) and OXi4503 (combretastatin A1-diphosphate or CA1P), several preclinical programs are underway that not only seek to broaden the therapeutic potential of our vascular disrupting agent (VDA) program but also investigate 2 new potential classes of agents. Specifically, these preclinical studies include:
- Investigating the potential use of CA4P in immuno-oncology in combination with checkpoint inhibitors in preclinical models. This work is being conducted in collaboration with researchers at the University of Florida and the University of Arhus.
- Pursuing the discovery of small-molecule anticancer agents belonging to a benzosuberene class of compounds in collaboration with researchers at Baylor University. These agents are potent inhibitors of tubulin polymerization and are highly cytotoxic against human cancer lines. Preclinical data have noted the relative simplicity of the chemical structure of these agents, which, coupled with their pronounced biological activity in vitro, could enable them to be potent “payloads” in antibody-drug conjugates (ADCs) and to be used as cytotoxic agents in other targeted delivery strategies.
- Pursuing small-molecule inhibitors of cysteine protease cathepsins (primarily cathepsin L and K) in collaboration with researchers at the University of Florida and the University of Arhus as potential anti-angiogenic and anti-metastatic agents.